Debbie S. Wang

More From Debbie S. Wang

Turnaround Takes Hold at Zimmer

We see meaningful improvement and remain confident in the company's wide moat.

Debbie S. Wang Sep 9, 2019

Putting LabCorp Under the Microscope

Debbie S. Wang Jul 10, 2019

Innovation Puts Medtronic in the Lead

The wide-moat company dominates medical technology.

Debbie S. Wang Jan 9, 2019

Undervalued Medtronic Looks Like a Healthy Buy

Debbie S. Wang Dec 7, 2018

What Zoetis' Acquisition Means for Idexx

Wide-moat Zoetis' purchase of Abaxis makes strategic sense but doesn't threaten narrow-moat Idexx Labs.

Debbie S. Wang Jun 18, 2018

Medtronic's Portfolio Is Unmatched

The wide-moat company leads the market in medical technology.

Debbie S. Wang Apr 16, 2018

Medtronic's Dominance Results in Wide Moat

Few can match the company's pervasive presence in hospitals.

Debbie S. Wang Feb 26, 2018

For Matters of the Heart (Valve), We Like Medtronic

Debbie S. Wang Feb 14, 2018

Is Healthcare Cost Sharing the Answer?

Policy research suggests consumers are not good at distinguishing high-value services from low-value.

Debbie S. Wang Oct 31, 2017

What CEO Departure Means for Zimmer Biomet

The company's wide economic moat, which primarily stems from surgeon switching costs, remains intact.

Debbie S. Wang Jul 12, 2017

A Healthcare Pick That's Moderately Shielded From Upheaval

Debbie S. Wang Apr 17, 2017

Zimmer Biomet's Regulatory Tussle

It will take many months for the wide-moat medical device firm to address the issues raised by the FDA, and this situation might drag on revenue growth in the near term, which could depress shares.

Debbie S. Wang Dec 16, 2016

Insulet Shares Swoon on Insurer Decision, but Fair Value Is Unchanged

We think the firm is largely insulated from UnitedHealth's choice of Medtronic.

Debbie S. Wang May 11, 2016

Coke Still on Track; Shares Fully Valued

First-quarter revenue growth for the wide-moat beverage maker trailed our full-year estimates, but we expect growth to increase later in the year, writes Morningstar's Adam Fleck.

Adam Fleck, CFA Apr 20, 2016

Steady Growth at J&J Reinforces Wide Moat, But Shares Overpriced

An anticipated slowdown in pharma giant’s drug business gives us some pause on the firm’s current valuation, but its long-term competitive advantages are intact.

Damien Conover, CFA Apr 19, 2016

4 Stocks to Profit From Obamacare’s Next Phase

Merck, Roche, Express Scripts, and LabCorp stand to benefit from an increased focus on cost control and improved outcomes.

Debbie S. Wang Jul 23, 2015

More About Debbie S. Wang

Debbie S. Wang is a senior equity analyst, AM Healthcare, for Morningstar*. She covers the medical-device, diagnostics, and animal health industries. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.

Prior to joining Morningstar 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald's, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.

Wang holds a bachelor’s degree in anthropology from Colgate University. She also holds a a master’s degree in business administration from the University of Chicago Booth School of Business.

* Morningstar Research Services LLC (“Morningstar”) is a wholly owned subsidiary of Morningstar, Inc